1 option
CADTH Canadian Drug Expert Committee recommendation : indication : giant cell arteritis. Tocilizumab (Actemra - Hoffmann-La Roche Limited) / CADTH Canadian Drug Expert Committee.
- Format:
- Book
- Author/Creator:
- CADTH Canadian Drug Expert Committee, author, issuing body.
- Language:
- English
- Subjects (All):
- Drugs--Safety measures.
- Drugs.
- Physical Description:
- 1 online resource
- Edition:
- Final.
- Place of Publication:
- Ottawa, ON : CADTH, 2018.
- Summary:
- The CADTH Canadian Drug Expert Committee (CDEC) recommends that tocilizumab be reimbursed for the treatment of giant cell arteritis (GCA) in adult patients, if the following criteria and conditions are met. At initiation of therapy, or with relapse, patients should be receiving prednisone. Duration of therapy with tocilizumab should be limited to 52 weeks per treatment course. Patients should be under the care of a physician with experience in the diagnosis and management of GCA. A reduction in price.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.